Immuron Delivers Robust Q3 Sales Growth on Strong Travelan® Demand
Immuron Limited (ASX: IMC) reported a strong third-quarter performance, driven by steady demand for its core product, Travelan. The company recorded global sales of AU$1.5 million during the quarter, marking a 16% year-on-year increase, while cumulative sales for the financial year reached AU$5.7 million, reflecting a 7% rise.
Australia remained the primary contributor, with quarterly sales increasing by 15%, supported by effective online marketing campaigns, broader retail distribution, and a rise in international travel. Canada emerged as a high-growth region, with sales surging significantly compared to both the prior year and previous quarter, aided by new store rollouts and promotional activities.
In the United States, sales growth was relatively stable, as marketing initiatives helped offset the adverse impact of currency movements. Overall, the company’s performance highlights improving brand visibility, successful expansion strategies, and growing consumer preference for digestive health products.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Immuron Delivers Robust Q3 Sales Growth on Strong Travelan® Demand
Immuron Limited (ASX: IMC) reported a strong third-quarter performance, driven by steady demand for its core product, Travelan. The company recorded global sales of AU$1.5 million during the quarter, marking a 16% year-on-year increase, while cumulative sales for the financial year reached AU$5.7 million, reflecting a 7% rise.
Australia remained the primary contributor, with quarterly sales increasing by 15%, supported by effective online marketing campaigns, broader retail distribution, and a rise in international travel. Canada emerged as a high-growth region, with sales surging significantly compared to both the prior year and previous quarter, aided by new store rollouts and promotional activities.
In the United States, sales growth was relatively stable, as marketing initiatives helped offset the adverse impact of currency movements. Overall, the company’s performance highlights improving brand visibility, successful expansion strategies, and growing consumer preference for digestive health products.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au